Value Investor
Start free

BridgeBio Oncology Therapeutics

BBOT on Nasdaq. Pharmaceutical preparations. Market value $289m.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Not a fit for our list right now

Why it could be worth it

What to watch out for

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to June 2026
-54.0%low

For every $100 of what the whole company costs, it produced $-54.01 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to June 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: not known. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$3.50 a share, at its 1-year low

Over the past year the price has ranged from $3.48 to $14.87.

Pays no dividend

Prices from Tuesday’s close (6 October).

Five years of cash, in billions

-0.1
-0.1
-0.2
2024202512 monthsto Jun '26
Revenue
n/an/a
Operating margin
n/an/a
Debt to equity
n/an/a
Shares outstanding
0.08bn0.08bn

Health checks

  • Free cash flow positive0 of 2 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)Not enough data
  • Profit backed by cash (accruals)Yes
  • DebtUnknown
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesRoughly flat

The quarter to June 2026

How the business did, compared with the same quarter a year earlier.

  • A loss of $56 million, compared with a loss of $28 million a year ago.
  • 59% more shares than a year ago. Each share owns a bit less of the company.
Profit by quarter
Profit by quarter
Quarter toAmount
September 2024-$17m
December 2024-$20m
March 2025-$22m
June 2025-$28m
September 2025-$45m
December 2025-$39m
March 2026-$42m
June 2026-$56m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
5 March 2026
Next quarterly (estimated, 10-Q)
10 November 2026

Who owns it

1 long-term investor we follow owns it, unchanged from 1 last quarter. 66 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

11 investors own more than 5%.

  • Bihua Chen
    Insider or founder
    at least 22.3%−0.3 pts
    (filed with 7 related holders)
    Since 1 July 2026
    What they said

    Item 4 is hereby amended and supplemented as follows: On July 1, 2026, Sponsor distributed 4,528,186 shares of Common Stock, pro rata, to its members for no consideration. Following such transaction, Sponsor holds no shares of Common Stock. As a result of Sponsor's pro rata…

    Read the filing
  • BridgeBio Pharma LLC
    Insider or founder
    at least 17.5%
    (filed with 1 related holder)
    Since 11 August 2025
    What they said

    The Reporting Persons acquired the Shares for investment purposes in the ordinary course of business. Immediately following the Effective Time of the Business Combination, Neil Kumar, Ph.D., Chief Executive Officer and a member of the board of directors of BBIO, and Frank P.…

    Read the filing
  • BlackRock Portfolio Management LLC
    Passive investor
    7.9%
    Since 31 March 2025
  • Cormorant Private Healthcare Fund III, LP
    Insider or founder
    7.5%
    Since 28 February 2025
    What they said

    Item 4 is hereby amended and supplemented as follows: On February 8, 2025, in connection with the appointment of Albert A. Holman III to the board of directors of the Issuer, the Sponsor transferred 30,000 Class B ordinary shares held by it to Mr. Holman. As reported by the…

    Read the filing
  • Cormorant Global Healthcare Master Fund, LP
    Insider or founder
    at least 7.5%−13.8 pts
    (filed with 2 related holders)
    Since 11 August 2025
    What they said

    Item 4 is hereby amended and supplemented as follows: As previously disclosed, on February 28, 2025, the Issuer (which was formerly known as Helix Acquisition Corp. II, "Helix") entered into a Business Combination Agreement (as amended on June 20, 2025, the "Business Combination…

    Read the filing
  • Deerfield Management Company, L.P.
    Passive investor
    at least 6.2%
    (filed with 5 related holders)
    Since 11 August 2025
  • BC Global Opportunities IX LP
    Passive investor
    at least 5.5%
    (filed with 3 related holders)
    Since 4 September 2025
  • Sculptor Capital LP
    Passive investor
    at least 5.1%
    (filed with 6 related holders)
    Since 17 July 2025
  • Millennium Management LLC
    Passive investor
    at least 4.7%
    (filed with 3 related holders)
    Since 30 June 2025
  • Citadel Advisors LLC
    Passive investor
    at least 3.2%
    (filed with 6 related holders)
    Since 30 September 2025
  • Adage Capital Management, L.P.
    Passive investor
    at least 1.9%
    (filed with 2 related holders)
    Since 30 September 2025
  • BlackRock, Inc.
    Passive investor
    Sold down below 5%
    Since 31 March 2025

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought or sold on the open market in the last 12 months.

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the serious warning signs we check for were found. 1 thing worth knowing.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 5 Mar 2026, plus the 10-Q filed 11 Aug 2026 and 7 later 8-Ks.

  • Changed auditor

    Worth knowing

    The company changed its auditor (the firm that checks its books) in the last two years.

    Cover page of the 10-K filed 5 Mar 2026: it names a different audit firm from the one named in the annual report before.

    From the cover page of the 10-K filed 5 March 2026. Open the filing

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.